Active, not recruitingPhase 1NCT04058756

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Studying Hinman syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Intervention
PDR001(drug)
Enrollment
120 target
Eligibility
18-100 years · All sexes
Timeline
20192030

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04058756 on ClinicalTrials.gov

Other trials for Hinman syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hinman syndrome

← Back to all trials